Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04SKW
|
|||
| Former ID |
DNC009253
|
|||
| Drug Name |
2,7-Bis[3-(ethylamino)propionamido]anthraquinone
|
|||
| Synonyms |
2,7-Bis[3-(ethylamino)propionamido]anthraquinone; CHEMBL481161; SCHEMBL4291487
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H28N4O4
|
|||
| Canonical SMILES |
CCNCCC(=O)NC1=CC2=C(C=C1)C(=O)C3=C(C2=O)C=C(C=C3)NC(=O)CCNCC
|
|||
| InChI |
1S/C24H28N4O4/c1-3-25-11-9-21(29)27-15-5-7-17-19(13-15)24(32)20-14-16(6-8-18(20)23(17)31)28-22(30)10-12-26-4-2/h5-8,13-14,25-26H,3-4,9-12H2,1-2H3,(H,27,29)(H,28,30)
|
|||
| InChIKey |
HJVRZEPJBMFCNQ-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | TERT messenger RNA (TERT mRNA) | Target Info | Inhibitor | [1] |
| KEGG Pathway | HTLV-I infection | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathway Interaction Database | Validated targets of C-MYC transcriptional activation | |||
| Regulation of Telomerase | ||||
| IL2 signaling events mediated by PI3K | ||||
| Regulation of nuclear beta catenin signaling and target gene transcription | ||||
| HIF-1-alpha transcription factor network | ||||
| Reactome | Formation of the beta-catenin:TCF transactivating complex | |||
| WikiPathways | TGF beta Signaling Pathway | |||
| miR-targeted genes in lymphocytes - TarBase | ||||
| miR-targeted genes in epithelium - TarBase | ||||
| Telomere Maintenance | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.